生物活性：Mitoxantrone-d8 (mitozantrone-d8) is the deuterium labeled Mitoxantrone. Mitoxantrone is a topoisomerase II inhibitor and also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Mitoxantrone-d8 相关抗体:
Phospho-PKC alpha (T638) Antibody
Phospho-PKC zeta (T560) Antibody
PKC alpha Antibody
PKC beta 1 Antibody
PKC beta 2 Antibody
PKC delta Antibody
PKC epsilon Antibody
PKC gamma Antibody
Ezrin Antibody (YA767)
PKC eta Antibody
TOP2A Antibody
DXd Antibody (YA897)
SN38 Antibody (YA923)
SGK1 Antibody (YA1525)
Topoisomerase I Antibody (YA2237)
PKC theta Antibody (YA3162)
Villin Antibody
Phospho-PKC alpha (Ser657) Antibody (YA1023)
Phospho-PKC alpha (Thr638) Antibody (YA1024)
PRKCQ Antibody (YA1106)
AMHR2 Antibody (YA1337)
Phospho-PKC (Ser660) Antibody (YA1394)
Phospho-PKC delta (Ser299) Antibody (YA2628)
Phospho-PKC zeta/lambda (Thr410/Thr412) Antibody (YA2631)
Phospho-PKC zeta (Thr560) Antibody (YA2679)
分子量：452.53
Formula：C22H20D8N4O6
CAS 号：1189974-82-0
非标记 CAS：65271-80-9
中文名称：米托蒽醌 d8
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (527 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7.
 [Content Brief]
[3]. Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
 [Content Brief]
[4]. Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8.
 [Content Brief]
[5]. Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62.
 [Content Brief]